Sunday, January 17, 2021 6:59:52 AM
Someone is exercising their warrants. To exercise those warrants they are giving the company $26,284,354.16. Those warrants cannot be exercised until February 3rd and at $3.19!
The warrant holders had until 2025 to decide if they wanted to exercise those warrants. They would not be giving the company that kind of money NOW unless they knew the price was going above that $3.19 strike price.
This could be a good indicator that good news is coming very soon.
Recent SONN News
- Sonnet BioTherapeutics Announces Launch of CEO Corner Platform • GlobeNewswire Inc. • 09/30/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/30/2024 12:30:28 PM
- Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split • GlobeNewswire Inc. • 09/25/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2024 12:36:17 PM
- Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors • GlobeNewswire Inc. • 09/18/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 09:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:08:40 PM
- Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series • GlobeNewswire Inc. • 09/04/2024 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 12:30:39 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/19/2024 09:28:17 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/19/2024 09:27:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 12:50:25 PM
- Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer • GlobeNewswire Inc. • 08/19/2024 12:45:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 12:45:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:41:20 PM
- Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/14/2024 12:35:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/09/2024 09:28:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 12:36:15 PM
- Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study • GlobeNewswire Inc. • 07/24/2024 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/15/2024 09:05:56 PM
- Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds • GlobeNewswire Inc. • 06/20/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 12:15:34 PM
- Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain • GlobeNewswire Inc. • 06/13/2024 12:00:00 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM